度普利尤单抗与内镜鼻窦手术治疗慢性鼻窦炎伴鼻息肉的经济学评价
本研究采用队列式马尔可夫决策树模型,对度普利尤单抗与内镜鼻窦手术治疗难治性慢性鼻窦炎伴鼻息肉进行10年时间跨度的成本-效果分析。结果显示度普利尤单抗策略成本为195,164美元,产生1.779质量调整生命年;内镜鼻窦手术策略成本为20,549美元,产生1.526质量调整生命年,增量成本-效果比为每增加1个质量调整生命年需691,691美元。概率敏感性分析表明内镜鼻窦手术在所有迭代中均更具成本-效果。
要点
- 度普利尤单抗策略成本195,164美元,产出1.779质量调整生命年。
- 内镜鼻窦手术策略成本20,549美元,产出1.526质量调整生命年。
- 增量成本-效果比为每增加1个质量调整生命年691,691美元,内镜鼻窦手术更具成本-效果。
核心结论
- 度普利尤单抗与内镜鼻窦手术可能显示相似的临床有效性,但内镜鼻窦手术仍是最具成本-效果的治疗选择,应继续作为对初始药物治疗难治的慢性鼻窦炎伴鼻息肉患者的标准治疗。
研究设计与样本
- 采用队列式马尔可夫决策树经济学评价,时间跨度为10年,比较度普利尤单抗治疗与内镜鼻窦手术后术后维持治疗两种策略。
- 对治疗有反应的患者继续维持治疗或度普利尤单抗治疗;无反应的患者接受内镜鼻窦手术。
- 主要结局指标为基于鼻窦炎结局测试(SNOT-22)评分计算的质量调整生命年增量成本,并进行了包括贴现情景和概率敏感性分析在内的敏感性分析。
主要发现
- 度普利尤单抗策略成本为195,164美元,产生1.779质量调整生命年。
- 内镜鼻窦手术策略成本为20,549美元,产生1.526质量调整生命年。
- 与内镜鼻窦手术相比,度普利尤单抗每增加1个单位质量调整生命年的增量成本为691,691美元。
- 概率敏感性分析表明,在所有迭代中内镜鼻窦手术均比度普利尤单抗更具成本-效果。
关键数值与推荐
- 度普利尤单抗策略:成本195,164美元,产出1.779质量调整生命年。
- 内镜鼻窦手术策略:成本20,549美元,产出1.526质量调整生命年。
- 增量成本-效果比:每增加1个质量调整生命年691,691美元。
临床怎么用
- 作者认为,对于对药物治疗难治的慢性鼻窦炎伴鼻息肉患者,内镜鼻窦手术仍是最具成本-效果的治疗选择,应继续作为标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dupilumab is a novel monoclonal antibody that recently received US Food and Drug Administration approval for the treatment of chronic rhinosinusitis with nasal polyps. Endoscopic sinus surgery (ESS) has been the mainstay of treatment for patients refractory to initial medical therapy. Data comparing the cost-effectiveness of these treatments are scarce. The objective of this study is to compare the cost-effectiveness of dupilumab and ESS treatment for patients with chronic rhinosinusitis with nasal polyps refractory to medical therapy. METHODS: A cohort-style Markov decision tree economic evaluation with 10-year time horizon was performed. The two comparative treatment strategies were dupilumab therapy or ESS followed by postoperative maintenance therapy. Patients with response to treatment continued with either maintenance or dupilumab therapy; patients with no response underwent ESS. The primary outcome measure was incremental cost per quality-adjusted life-year calculated from Sino-Nasal Outcome Test (SNOT-22) scores. Sensitivity analyses were performed including discounting scenarios and a probabilistic sensitivity analysis. RESULTS: The dupilumab strategy cost $195,164 and produced 1.779 quality-adjusted life-years. The ESS strategy cost $20,549 and produced 1.526 quality-adjusted life-years. This implies an incremental cost of $691,691 for dupilumab for every 1-unit increase in quality-adjusted life-year compared with ESS. Probability sensitivity analysis indicated that ESS was more cost-effective than dupilumab in all iterations. CONCLUSIONS: While dupilumab and ESS may demonstrate similar clinical effectiveness, ESS remains the most cost-effective treatment option and should remain the standard of care for patients with chronic rhinosinusitis with nasal polyps refractory to medical therapy.
引用
- Parasher AK, Gliksman M, Segarra D, et al. Economic Evaluation of Dupilumab Versus Endoscopic Sinus Surgery for the Treatment of Chronic Rhinosinusitis With Nasal Polyps. Int Forum Allergy Rhinol. 2022. PMID: 34874120. doi:10.1002/alr.22936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。